Answers are grounded in this paper and cite their sources.
// Peter A. Fasching 1, 2, * , Lothar Häberle 1, 3, * , Brigitte Rack 4 , Liang Li 5, 6 , Alexander Hein 1 , Arif B. Ekici 7 , Andre Reis 7 , Michael P. Lux 1 , Julie M. Cunningham 8 , Matthias Ruebner 1 , Gergory Jenkins 9 , Brooke Fridley 9, 10 , Andreas Schneeweiss 11 , Hans Tesch 12 , Werner Lichtenegger 13 , Tanja Fehm 14 , Georg Heinrich 15 , Mahdi Rezai 16 , Matthias W. Beckmann 1 , Wolfgang Janni 17 , Richard M. Weinshilboum 5 and Liewei Wang 5 1 Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany 2 Department of Medicine, Division of Hematology/Oncology, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA 3 Department of Gynecology and Obstetrics, Biostatistics Unit, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany 4 Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Munich, Germany 5 Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School-Mayo Foundation, Rochester, MN, USA 6 Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China 7 Institute of Human Genetics, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany 8 Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA 9 Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA 10 Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA 11 Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany 12 Department of Oncology, Onkologie Bethanien, Frankfurt, Germany 13 Department of Gynecology and Obstetrics, Charité University Hospital, Campus Virchow, Berlin, Germany 14 Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Heinrich Heine University, Düsseldorf, Germany 15 Department of Gynecologic Oncology, Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany 16 Department of Breast Diseases, Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany 17 Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany * These authors have contributed equally to this work Correspondence to: Peter Fasching, email: peter.fasching@uk-erlangen.de Keywords: chemotherapy, neutropenia, leukopenia, SNP, polymorphism Received: January 05, 2017 Accepted: April 06, 2017 Published: May 09, 2017 ABSTRACT Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS prospective phase III chemotherapy study. All patients (n = 1678) received three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by three cycles of docetaxel or docetaxel/gemcitabine, depending on randomization. Germline DNA was genotyped for 246 SNPs selected from a previous genome-wide association study (GWAS) in a panel of lymphoblastoid cell lines, with gemcitabine toxicity as the phenotype. All SNPs were tested for their value in predicting grade 3 or 4 neutropenic or leukopenic events (NLEs). Their prognostic value in relation to overall survival and disease-free survival was also tested. None of the SNPs was found to be predictive for NLEs during treatment with docetaxel/gemcitabine. Two SNPs in and close to the PIGB gene significantly improved the prediction of NLEs after FEC, in addition to the factors of age and body surface area. The top SNP (rs12050587) had an odds ratio of 1.38 per minor allele (95% confidence interval, 1.17 to 1.62). No associations were identified for predicting disease-free or overall survival. Genetic variance in the PIGB gene may play a role in determining interindividual differences in relation to hematotoxicity after FEC chemotherapy.
No takes yet. Share an insight, caveat, or question.
Fasching et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: